|
1
|
Dicken BJ, Bigam DL, Cass C, Mackey JR,
Joy AA and Hamilton SM: Gastric adenocarcinoma: Review and
considerations for future directions. Ann Surg. 241:27–39.
2005.
|
|
2
|
Nissan A, Garofalo A and Esquivel J:
Cytoreductive surgery and hyperthermic intra-peritoneal
chemotherapy (HIPEC) for gastric adenocarcinoma: Why haven't we
reached the promised land? J Surg Oncol. 102:359–360. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glehen O, Mohamed F and Gilly FN:
Peritoneal carcinomatosis from digestive tract cancer: New
management by cytoreductive surgery and intraperitoneal
chemohyperthermia. Lancet Oncol. 5:219–228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takei Y, Takigahira M, Mihara K, Tarumi Y
and Yanagihara K: The metastasis-associated microRNA miR-516a-3p is
a novel therapeutic target for inhibiting peritoneal dissemination
of human scirrhous gastric cancer. Cancer Res. 71:1442–1453. 2011.
View Article : Google Scholar
|
|
8
|
Motoyama K, Inoue H, Mimori K, Tanaka F,
Kojima K, Uetake H, Sugihara K and Mori M: Clinicopathological and
prognostic significance of PDCD4 and microRNA-21 in human gastric
cancer. Int J Oncol. 36:1089–1095. 2010.PubMed/NCBI
|
|
9
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar
|
|
10
|
Zhang Z, Liu S, Shi R and Zhao G: miR-27
promotes human gastric cancer cell metastasis by inducing
epithelial-to-mesenchymal transition. Cancer Genet. 204:486–491.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okugawa Y, Inoue Y, Tanaka K, Kawamura M,
Saigusa S, Toiyama Y, Ohi M, Uchida K, Mohri Y and Kusunoki M: Smad
interacting protein 1 (SIP1) is associated with peritoneal
carcinomatosis in intestinal type gastric cancer. Clin Exp
Metastasis. 30:417–429. 2013. View Article : Google Scholar
|
|
12
|
Takahashi RU, Takeshita F, Honma K, Ono M,
Kato K and Ochiya T: Ribophorin II regulates breast tumor
initiation and metastasis through the functional suppression of
GSK3β. Sci Rep. 3:24742013. View Article : Google Scholar
|
|
13
|
Japanese Gastric Cancer Association:
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric
Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nguyen DX, Bos PD and Massagué J:
Metastasis: From dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Löffler C, Rao VV and Hansmann I: Mapping
of the ribophorin II (RPN II) gene to human chromosome 20q12–q13.1
by in-situ hybridization. Hum Genet. 87:221–222. 1991. View Article : Google Scholar
|
|
17
|
Testa JR, Kinnealey A, Rowley JD, Golde DW
and Potter D: Deletion of the long arm of chromosome 20
[del(20)(q11)] in myeloid disorders. Blood. 52:868–877.
1978.PubMed/NCBI
|
|
18
|
Kelleher DJ, Kreibich G and Gilmore R:
Oligosaccharyltransferase activity is associated with a protein
complex composed of ribophorins I and II and a 48 kd protein. Cell.
69:55–65. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kelleher DJ and Gilmore R: An evolving
view of the eukaryotic oligosaccharyltransferase. Glycobiology.
16:47R–62R. 2006. View Article : Google Scholar
|
|
20
|
Honma K, Iwao-Koizumi K, Takeshita F,
Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K and Ochiya T:
RPN2 gene confers docetaxel resistance in breast cancer. Nat Med.
14:939–948. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen QY, Jiao DM, Wang J, Hu H, Tang X,
Chen J, Mou H and Lu W: miR-206 regulates cisplatin resistance and
EMT in human lung adenocarcinoma cells partly by targeting MET.
Oncotarget. 7:24510–24526. 2016.PubMed/NCBI
|
|
22
|
Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z,
Jiang M, Chen M, Wang X, Kang Y, Zhou Y, et al: Targeting the
miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance
in multiple myeloma. Cancer Res. 75:4384–4397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng
L, Shi Y, Wang H, Yin B, Xia J, et al: Down-regulation of miR-223
reverses epithelial-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Oncotarget. 6:1740–1749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yukimoto K, Nakata B, Muguruma K, Yashiro
M, Ohira M, Ishikawa T, Hino M and Hirakawa K: Apoptosis and
thymidylate synthase inductions by 5-fluorouracil in gastric cancer
cells with or without p53 mutation. Int J Oncol. 19:373–378.
2001.PubMed/NCBI
|
|
25
|
Endo F, Nishizuka SS, Kume K, Ishida K,
Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K and Wakabayashi G: A
compensatory role of NF-κB to p53 in response to 5-FU-based
chemotherapy for gastric cancer cell lines. PLoS One. 9:e901552014.
View Article : Google Scholar
|
|
26
|
Fujita Y, Yagishita S, Takeshita F,
Yamamoto Y, Kuwano K and Ochiya T: Prognostic and therapeutic
impact of RPN2-mediated tumor malignancy in non-small-cell lung
cancer. Oncotarget. 6:3335–3345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boyer B, Vallés AM and Edme N: Induction
and regulation of epithelial-mesenchymal transitions. Biochem
Pharmacol. 60:1091–1099. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim T, Veronese A, Pichiorri F, Lee TJ,
Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, et al:
p53 regulates epithelial-mesenchymal transition through microRNAs
targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
